Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,573 matching trials from the local directory fallback.
Filters: Intervention: therapy Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 8:16 PM EDT
Active, not recruiting Phase 1 Interventional

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728
View directory record Official record
Conditions
Glioblastoma
Interventions
Radiotherapy, Temozolomide, [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 19, 2026, 2:31 AM EDT
Active, not recruiting Not applicable Interventional

Chronic Pain Management In Primary Care Using Behavioral Health Consultants

NCT04680000
View directory record Official record
Conditions
Chronic Pain
Interventions
BCBT-CP Booster, Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)
Other · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 10:10 AM EDT
Active, not recruiting Phase 1 Interventional

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

NCT03528642
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Interventions
Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
Other · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 4:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

NCT03197506
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
Radiation · Other · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 11:49 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

NCT02792582
View directory record Official record
Conditions
Craniopharyngioma
Interventions
Proton Therapy, Surgery
Radiation · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 8:00 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

NCT04481919
View directory record Official record
Conditions
Acute Heart Failure, Heart Failure
Interventions
Protocolized diuretic therapy
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
19 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 2:55 PM EDT
Active, not recruiting No phase listed Observational

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

NCT05863052
View directory record Official record
Conditions
Gastrointestinal Cancer, Immune Checkpoint Inhibitors, Melanoma, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma
Interventions
Immunotherapy
Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • Albuquerque, New Mexico • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 8:47 PM EDT
Active, not recruiting Phase 1 Interventional

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

NCT05141513
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 8:05 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial

NCT05077735
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Computed Tomography Scan, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 11:09 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Brachytherapy, Carboplatin, Cisplatin, Cisplatin (as radiosensitizer), Docetaxel, External Beam Radiotherapy (EBRT), Paclitaxel, Pembrolizumab, Placebo for pembrolizumab
Radiation · Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

NCT04516135
View directory record Official record
Conditions
Metastatic Malignant Female Reproductive System Neoplasm
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Volume Modulated Arc Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Camden, New Jersey • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 2:32 AM EDT
Active, not recruiting Not applicable Interventional

Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer

NCT04266886
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Metastatic Cervical Cancer, Recurrent Malignant Female Reproductive System Neoplasm
Interventions
Best Practice, Hypnotherapy, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 2:20 AM EDT
Active, not recruiting Phase 1 Interventional

Cryotherapy for Locally Advanced Esophageal Cancer

NCT04248582
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cryotherapy
Device
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 11:03 PM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

NCT03410043
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 16, 2026, 12:37 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT03391869
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Ipilimumab, Local Consolidation Therapy, Nivolumab, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Procedure · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 4:56 PM EDT
Active, not recruiting Not applicable Interventional

Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies

NCT02221700
View directory record Official record
Conditions
Malignant Breast Neoplasm, Malignant Digestive System Neoplasm, Peripheral Neuropathy
Interventions
Massage Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 1, 2026, 8:19 PM EDT
Active, not recruiting Phase 3 Interventional

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT06205316
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
Drug · Procedure · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Albert Lea, Minnesota • Mankato, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

Rapid Administration Pilot for Infusing Dinutuximab

NCT05421897
View directory record Official record
Conditions
Neuroblastoma
Interventions
Dinutuximab with Chemotherapy
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 7:18 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Sleep, Sleep-related Outcomes, and Biomarkers in Veterans

NCT03968874
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Light box therapy, Negative Ion Generator
Device
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years to 88 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 5:16 AM EDT
Active, not recruiting Not applicable Interventional

Rapid Entrainment and Signal-guided Neuromodulation for Behavioral Health

NCT07812987
View directory record Official record
Conditions
ADHD, Anxiety, Depression Disorders, Executive Function, PTSD, Post-traumatic Stress, Sleep Disturbance, Substance Use
Interventions
AIP-Informed Integrative Psychotherapy, Audiovisual Entrainment, Breathwork-Based Auditory Driving Entropy Module (BADEM), Regulated Breathing and Autonomic Regulation, Transcranial Electrical Stimulation, Transcutaneous Auricular Vagus Nerve Stimulation, Vibroacoustic Stimulation
Behavioral · Device
Lead sponsor
Tactical Mind Research Coalition, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 5:04 AM EDT
Active, not recruiting Phase 1 Interventional

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

NCT06459869
View directory record Official record
Conditions
Locally Advanced Rectal Cancer (LARC)
Interventions
Capecitabine oral administration, NG-350A IV administration, Radiotherapy
Drug · Radiation
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Orlando, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 3:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571
View directory record Official record
Conditions
Acute Myeloid Leukemias
Interventions
Chemotherapy Regimen, HiDAC, Revumenib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Goodyear, Arizona • Burbank, California • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 11:29 PM EDT
Active, not recruiting Not applicable Interventional

A Female-Specific CBT Group for Veteran Women With Alcohol Use Disorder in VA Primary Care Settings

NCT06118346
View directory record Official record
Conditions
Alcohol Use Disorder, Risky Health Behavior
Interventions
Female-Specific Cognitive Behavioral Therapy (FS-CBT), Usual Care
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 7:05 PM EDT